Current pharmacological treatments for COVID‐19: What's next?

Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of pharmacology 2020-11, Vol.177 (21), p.4813-4824
Hauptverfasser:	Scavone, Cristina, Brusco, Simona, Bertini, Michele, Sportiello, Liberata, Rafaniello, Concetta, Zoccoli, Alice, Berrino, Liberato, Racagni, Giorgio, Rossi, Francesco, Capuano, Annalisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals antiinflammatory agents Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - pharmacology Antiviral drugs antivirals Betacoronavirus - isolation & purification clinical practice clinical research Clinical trials Coronavirus Infections - drug therapy Coronavirus Infections - virology COVID-19 Drug Repositioning Drug therapy Drugs Humans Immunosuppressive agents immuno‐modulatory agents Inflammation Lopinavir Pandemics Patients pharmacological treatments Pneumonia, Viral - drug therapy Pneumonia, Viral - virology Review Ritonavir SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Themed Issue: Review Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!